Loma Therapeutics
Developer of a viral-vector immunotherapy platform targeting HPV-positive cancers. The company focuses on delivering full-length HPV antigens and an integrated genetic adjuvant via replication-deficient viral vectors to elicit broad CD8+ and CD4+ T-cell responses. Activities described include preclinical efficacy and immunogenicity studies, human ex vivo immunization assays, CMC planning, and preparation for clinical translation.
Industries
Nr. of Employees
small (1-50)
Products
HPV-targeted viral-vector immunotherapy (clinical candidate)
A replication-deficient viral-vector immunotherapy encoding multiple full-length HPV antigens and a genetic adjuvant, designed to induce broad cytotoxic T-cell responses against HPV-infected and HPV-positive tumor cells.
HPV-targeted viral-vector immunotherapy (clinical candidate)
A replication-deficient viral-vector immunotherapy encoding multiple full-length HPV antigens and a genetic adjuvant, designed to induce broad cytotoxic T-cell responses against HPV-infected and HPV-positive tumor cells.
Services
Design and execution of in vivo immunogenicity and tumor-efficacy studies in rodents and non-human primates, including combination therapy assessment.
Ex vivo assays using donor PBMCs and transduced dendritic cells to assess induction and functionality of HPV-specific T cells.
Collaborative engagement with academic, clinical, and institutional partners to support clinical translation, monitoring implementation, and region-specific planning.
Design and execution of in vivo immunogenicity and tumor-efficacy studies in rodents and non-human primates, including combination therapy assessment.
Ex vivo assays using donor PBMCs and transduced dendritic cells to assess induction and functionality of HPV-specific T cells.
Collaborative engagement with academic, clinical, and institutional partners to support clinical translation, monitoring implementation, and region-specific planning.
Expertise Areas
- Therapeutic vaccine development
- Preclinical immunology and tumor models
- Viral vector engineering
- Translational immunology (human ex vivo assays)
Key Technologies
- Replication-deficient viral vectors (adenoviral-based delivery)
- Full-length multi-antigen construct design
- Genetic adjuvant integration
- Dendritic cell transduction and PBMC co-culture assays
News & Updates
Selected to join the Venture House program to access mentorship, facilities, and networks supporting development of the therapeutic vaccine.
Publication reporting ex vivo human immunization assays showing induction of functional CD8+ and CD4+ T cells and reduced exhaustion for certain antigen targets.
Preclinical study published in Cancer Immunology Research describing in vitro QC, immunogenicity, and tumor-growth inhibition in murine models.
Recipient in a consortium awarded 28.65M DKK (approx. 3.9M EUR) to advance immunotherapy to clinical stage, study immune dynamics, and implement an HPV DNA-based monitoring system; company to receive ~1.3M EUR.
Recipient of the Women TechEU grant supporting female-led deep-tech startups in Europe.
Selected to join the Venture House program to access mentorship, facilities, and networks supporting development of the therapeutic vaccine.
Publication reporting ex vivo human immunization assays showing induction of functional CD8+ and CD4+ T cells and reduced exhaustion for certain antigen targets.
Preclinical study published in Cancer Immunology Research describing in vitro QC, immunogenicity, and tumor-growth inhibition in murine models.
Recipient in a consortium awarded 28.65M DKK (approx. 3.9M EUR) to advance immunotherapy to clinical stage, study immune dynamics, and implement an HPV DNA-based monitoring system; company to receive ~1.3M EUR.
Recipient of the Women TechEU grant supporting female-led deep-tech startups in Europe.